LifeMD (LFMD) Cash & Equivalents (2012 - 2025)

LifeMD has reported Cash & Equivalents for 14 years, with the latest figure at $36.8 million in Q4 2025.

• For the quarter ending Q4 2025, Cash & Equivalents rose 12.66% year-over-year to $36.8 million; the trailing twelve-month figure through Dec 2025 stood at $36.8 million (up 12.66% YoY), and the FY2025 full-year result was $36.8 million, up 12.66% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $36.8 million, up from $23.8 million in the prior quarter.
• The five-year high for Cash & Equivalents was $41.3 million in Q4 2021, with the low at $4.0 million in Q4 2022.
• Historically, Cash & Equivalents has averaged $23.6 million across 5 years, with a median of $24.4 million in 2022.
• Annual changes were most pronounced in 2021 — Cash & Equivalents surged 5080.48% — and 2022, when it plunged 90.42%.
• LifeMD's Cash & Equivalents stood at $41.3 million in 2021, then sank by 90.42% to $4.0 million in 2022, then surged by 737.26% to $33.1 million in 2023, then declined by 1.49% to $32.7 million in 2024, then increased by 12.66% to $36.8 million in 2025.
• The last three Cash & Equivalents figures came in at $36.8 million (Q4 2025), $23.8 million (Q3 2025), and $36.2 million (Q2 2025), per Business Quant data.